Published Study Reveals Next Pharmaceuticals' Flavoxine Reduces Multiple Heart Health Risk Factors Including High CholesterolSALINAS, Calif.--(BUSINESS WIRE)--Jun 19, 2008 - Next Pharmaceuticals announced today the results of their placebo-controlled, randomized, double-blind clinical trial, which revealed multiple heart health benefits of Flavoxine. The published study concluded that Flavoxine significantly reduced LDL-cholesterol and triglycerides, while it significantly decreased blood pressure and fasting blood glucose. The study also found that Flavoxine increased HDL-cholesterol (good cholesterol), and may be helpful in weight reduction, as the overweight individuals in the study lost an average of 5% of their body weight in 8 weeks.
The study was recently published in Nutrition Journal, an open access, peer-reviewed, online journal. The published clinical trial is also available at PubMed and archived in PubMed Central.
"Flavoxine is the result of Next Pharmaceuticals devoting many years to finding a natural formula for heart health that would have multiple benefits," said Charles Kosmont, CEO of Next Pharmaceuticals. "We are very satisfied with the results of this study and the benefits Flavoxine will provide to people who prefer a safe and effective natural approach to their heart health."
The 8-week, placebo-controlled study was conducted with four groups, comparing the effects of Flavoxine to placebo in overweight and normal weight. The subjects were given Flavoxine (a combination of two botanical extracts; Phellodendron amurense bark and Citrus sinensis peel) or a matching placebo.
Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were reported. Flavoxine administration was associated with a general improvement in lipid levels. Both the overweight and normal weight treatment groups had significant reductions in triglycerides and LDL-cholesterol, as well as a significant increase in HDL-cholesterol compared to their respective control groups.
Overall there were decreases in blood pressure in both overweight and normal weight treatment groups compared to placebo. There was also a significant decrease in fasting glucose levels in the overweight treatment group. The overweight treatment group also lost a significant amount of weight over the duration of the study.
Next Pharmaceuticals develops new, patented, natural ingredients for healthy living products in the dietary supplement, food and beverage industries. The goal of the Company is to expand self-care and preventative health maintenance. Next has successfully developed six plant extracts, both patented and proprietary, plus Chromulin(TM), a new form of the essential trace mineral chromium for potentiating insulin. These products have significantly expanded the choices for self-care products, while providing large consumer brands with powerful product differentiation. Through the application of pharmaceutical technologies to natural botanical materials, including citrus fruits, Next has developed Relora(R) for relaxation and stress-related appetite control, Seditol(R) for better quality of sleep, Nexrutine(R) for inflammation, Citri-Z(R) for heart health; Flavoxine(TM) for healthy cholesterol, and Citrofen(TM) for mobility and joint comfort.
For all media inquiries, please contact Connie St. John at 415-454-2243 or 415-302-7438 (mobile).
For Next Pharmaceuticals
Connie St. John, 415-454-2243 (Media)
Posted: June 2008